BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37606530)

  • 21. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
    Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
    Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
    PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells.
    Zheng Y; Zhang H; Xiao C; Deng Z; Fan T; Zheng B; Li C; He J
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
    Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
    Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8
    Wang CI; Chang YF; Sie ZL; Ho AS; Chang JS; Peng CL; Cheng CC
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer.
    Li Z; Xue H; Li J; Zheng Z; Liu Z; Dong X; Wang H; Chen J; Xu S
    J Exp Clin Cancer Res; 2024 Mar; 43(1):89. PubMed ID: 38520004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
    Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
    Liu Z; Wen J; Hu F; Wang J; Hu C; Zhang W
    Cancer Sci; 2022 Feb; 113(2):432-445. PubMed ID: 34927311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
    Sp N; Kang DY; Lee JM; Jang KJ
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
    Du W; Zhu J; Zeng Y; Liu T; Zhang Y; Cai T; Fu Y; Zhang W; Zhang R; Liu Z; Huang JA
    Cell Death Differ; 2021 Apr; 28(4):1284-1300. PubMed ID: 33139930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
    Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
    J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
    Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
    J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression.
    Wang SS; Liu Y; Zhang XT; Yu DQ
    Tohoku J Exp Med; 2023 May; 260(1):63-73. PubMed ID: 36823182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
    Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
    Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
    Wang YF; Liu F; Sherwin S; Farrelly M; Yan XG; Croft A; Liu T; Jin L; Zhang XD; Jiang CC
    J Invest Dermatol; 2018 Apr; 138(4):922-932. PubMed ID: 29174371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation.
    Cao D; Chen D; Xia JN; Wang WY; Zhu GY; Chen LW; Zhang C; Tan B; Li H; Li YW
    Biomed Pharmacother; 2022 Nov; 155():113705. PubMed ID: 36271541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha5 nicotinic acetylcholine receptor mediated immune escape of lung adenocarcinoma via STAT3/Jab1-PD-L1 signalling.
    Zhu P; Jin Z; Kang G; Jia Y; Liu D; Zhang Q; Guo F; Jia Y; Jiao Y; Li J; Sun H; Ma X
    Cell Commun Signal; 2022 Aug; 20(1):121. PubMed ID: 35971127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evodiamine suppresses non-small cell lung cancer by elevating CD8
    Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
    J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.